Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 7 | 2022 | 98 | 3.940 |
Why?
|
| Blood Coagulation Disorders | 4 | 2022 | 33 | 2.820 |
Why?
|
| Sclerotherapy | 3 | 2022 | 45 | 2.130 |
Why?
|
| Anemia, Sickle Cell | 2 | 2021 | 96 | 0.880 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2022 | 4 | 0.850 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 7 | 0.850 |
Why?
|
| Bleomycin | 2 | 2022 | 35 | 0.820 |
Why?
|
| Pupil | 1 | 2021 | 30 | 0.800 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 72 | 0.770 |
Why?
|
| Thrombelastography | 1 | 2020 | 26 | 0.740 |
Why?
|
| Hemostasis | 1 | 2020 | 55 | 0.720 |
Why?
|
| Sirolimus | 1 | 2019 | 62 | 0.650 |
Why?
|
| Adolescent | 9 | 2024 | 6340 | 0.590 |
Why?
|
| Dapsone | 1 | 2017 | 4 | 0.590 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 6 | 0.590 |
Why?
|
| Child | 11 | 2024 | 6824 | 0.590 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 78 | 0.580 |
Why?
|
| Young Adult | 7 | 2024 | 3936 | 0.580 |
Why?
|
| Child, Preschool | 8 | 2024 | 3853 | 0.580 |
Why?
|
| Fever | 1 | 2017 | 117 | 0.550 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 97 | 0.540 |
Why?
|
| Anticoagulants | 1 | 2018 | 254 | 0.500 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2023 | 25 | 0.390 |
Why?
|
| Adult | 7 | 2024 | 13160 | 0.380 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 99 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6117 | 0.300 |
Why?
|
| Humans | 16 | 2024 | 49827 | 0.300 |
Why?
|
| Male | 10 | 2024 | 25093 | 0.290 |
Why?
|
| Pain | 2 | 2021 | 380 | 0.290 |
Why?
|
| Treatment Outcome | 5 | 2022 | 5138 | 0.270 |
Why?
|
| Hemorrhage | 3 | 2024 | 202 | 0.270 |
Why?
|
| Female | 10 | 2024 | 26329 | 0.250 |
Why?
|
| Infant | 4 | 2024 | 3551 | 0.230 |
Why?
|
| von Willebrand Diseases | 1 | 2024 | 22 | 0.230 |
Why?
|
| Hemophilia A | 1 | 2024 | 25 | 0.230 |
Why?
|
| Renal Insufficiency | 2 | 2014 | 109 | 0.220 |
Why?
|
| Sclerosing Solutions | 1 | 2022 | 14 | 0.210 |
Why?
|
| Anxiety | 1 | 2024 | 269 | 0.200 |
Why?
|
| Mental Health | 1 | 2024 | 216 | 0.200 |
Why?
|
| Arteriovenous Malformations | 1 | 2022 | 66 | 0.200 |
Why?
|
| Analgesics | 1 | 2021 | 101 | 0.190 |
Why?
|
| Blood Coagulation Tests | 1 | 2020 | 19 | 0.190 |
Why?
|
| Pain Measurement | 1 | 2021 | 236 | 0.190 |
Why?
|
| Databases, Factual | 1 | 2024 | 664 | 0.190 |
Why?
|
| Blood Coagulation | 1 | 2020 | 57 | 0.180 |
Why?
|
| Middle Aged | 5 | 2024 | 11997 | 0.180 |
Why?
|
| Piebaldism | 1 | 2019 | 1 | 0.170 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 17 | 0.170 |
Why?
|
| Kidney | 2 | 2014 | 665 | 0.170 |
Why?
|
| Pancytopenia | 1 | 2019 | 37 | 0.170 |
Why?
|
| Depression | 1 | 2024 | 564 | 0.160 |
Why?
|
| Diarrhea | 1 | 2019 | 91 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2022 | 2344 | 0.160 |
Why?
|
| Heart Failure | 2 | 2014 | 454 | 0.160 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2018 | 10 | 0.160 |
Why?
|
| Fibrinogen | 1 | 2018 | 31 | 0.160 |
Why?
|
| Antisickling Agents | 1 | 2017 | 13 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2017 | 30 | 0.150 |
Why?
|
| Pneumocystis Infections | 1 | 2017 | 4 | 0.150 |
Why?
|
| Seizures | 1 | 2019 | 196 | 0.150 |
Why?
|
| Pneumocystis carinii | 1 | 2017 | 4 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 44 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2018 | 423 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 9272 | 0.130 |
Why?
|
| Hemodiafiltration | 1 | 2014 | 3 | 0.120 |
Why?
|
| Models, Biological | 1 | 2017 | 728 | 0.120 |
Why?
|
| Hemofiltration | 1 | 2013 | 7 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2179 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 987 | 0.090 |
Why?
|
| Prognosis | 2 | 2023 | 1952 | 0.070 |
Why?
|
| Ultrafiltration | 2 | 2014 | 7 | 0.060 |
Why?
|
| Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
|
| Etoposide | 1 | 2023 | 72 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2024 | 116 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 116 | 0.060 |
Why?
|
| Acute Disease | 2 | 2014 | 369 | 0.050 |
Why?
|
| Esthetics, Dental | 1 | 2022 | 21 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 3125 | 0.050 |
Why?
|
| Head | 1 | 2022 | 73 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 99 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 904 | 0.050 |
Why?
|
| Prevalence | 1 | 2024 | 943 | 0.050 |
Why?
|
| Siblings | 1 | 2019 | 33 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 121 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 181 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 376 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2744 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 3619 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1374 | 0.030 |
Why?
|
| United States | 1 | 2024 | 4838 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 99 | 0.030 |
Why?
|
| Heart Rate | 1 | 2013 | 292 | 0.030 |
Why?
|
| Hospitalization | 1 | 2013 | 653 | 0.020 |
Why?
|